SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTPRNewsWire • 11/03/23
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 11/01/23
Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever TestInvestors Business Daily • 10/31/23
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPTBusiness Wire • 10/31/23
Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goalMarket Watch • 10/31/23
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene TherapyInvestors Business Daily • 10/30/23
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular DystrophyBusiness Wire • 10/30/23
Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular DystrophySeeking Alpha • 10/25/23
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/25/23
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.6%: Here's is How to TradeZacks Investment Research • 10/09/23
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic YearBusiness Wire • 09/07/23
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceBusiness Wire • 09/05/23